Implementation considerations for integrated face and respiratory protection: a qualitative study.

Publication date: Jun 01, 2025

The implementation of an innovative form of personal protective equipment (PPE) as an infection and prevention control measure for respiratory transmissible diseases is complex, with several elements to be addressed. To make considerations for integrated face and respiratory protection implementation in clinical settings. This was a multi-site qualitative study with 87 health workers that compared traditional PPE or powered air-purifying (PAPR) respirators with lightweight PAPR (L-PAPR). Semi-structured interviews were performed based on the Consolidated Framework for Implementation Research (CFIR). Insights into L-PAPR implementation were found. The advantages include enhanced sense of protection, pleasant ventilation, good visibility for both health worker and patient, no fogging of the visor interior, no movement restriction, and easy disinfection process. To enhance usability some barriers should be tackled: reduction of facial pressure; better accommodation for glasses and corrective lenses; reduction of number of steps for assembling the device; infrastructure provision for storage, charging and disinfection of the device; training of health workers for assembling, donning and doffing; and the cost benefit of implementation. L-PAPR was overall perceived with advantages by many participants, and can be considered a potential option of PPE to be implemented to protect health workers during outbreaks of respiratory transmissible diseases.

Concepts Keywords
Advantages Adult
Diseases COVID-19
Interviews Female
Qualitative Health Personnel
Respirators Humans
Implementation
Infection Control
Infection prevention
Interviews as Topic
Male
Middle Aged
Personal Protective Equipment
Personal protective equipment
Qualitative Research
Qualitative research
Respiratory protective device
Respiratory Protective Devices

Semantics

Type Source Name
disease MESH infection
disease IDO site
drug DRUGBANK Medical air
disease IDO process
drug DRUGBANK Tropicamide
disease MESH COVID-19
disease MESH Infectious Disease Transmission Patient-to-Professional

Original Article

(Visited 1 times, 1 visits today)